A genetic screen for mutations affecting embryogenesis in the medaka, Oryzias latipes, identified a mutant, whiteout (who), that exhibited hypochromic anemia. The who mutant initially had the normal number of blood cells, but it then gradually decreased during the embryonic and larval stages. The blood cells in the who mutants show an elongated morphology and little hemoglobin activity. Genetic mapping localized who to the vicinity of a LG12 marker, olgc1. By utilizing the highly conserved synteny between medaka and pufferfish, we identified a gene for d-aminolevulinic acid dehydratase (ALAD), which is the second enzyme in the heme synthetic pathway, as a candidate for who. We found a missense mutation in the alad gene that was tightly linked to the who phenotype, strongly suggesting that the hypochromic anemia phenotype in the who mutant is caused by a loss of the alad function. Thus, who mutants represent a model for the human disease ALAD-deficiency porphyria. q
Introduction
d-Aminolevulinic acid dehydratase (ALAD) is the second enzyme in the pathway for heme synthesis, and it catalyzes the condensation of two molecules of 5-aminolevulinic acid (ALA) to form one molecule of the monopyrrole porphobilinogen (PBG) . Homozygous mutations in the human ALAD gene cause ALAD-deficiency porphyria (ADP), a very rare autosomal recessive disorder. Patients with this disorder have symptoms of acute hepatic porphyria such as abdominal pain, vomiting, pain in the arms and legs, and neuropathy.
Hematopoiesis in vertebrates is generally categorized into two stages, namely, primitive (embryonic) hematopoiesis and definitive hematopoiesis. The primitive hematopoiesis primarily produces embryonic red blood cells, whereas definitive hematopoiesis produces definitive erythrocytes, myeloid cells and lymphocytes. In most vertebrates, primitive hematopoiesis is initiated in the blood islands of the yolk. However, in the teleosts such as the medaka and zebrafish, the first mature blood cells appear in the intermediate cell mass (ICM), a region in the trunk ventral to the notochord. The medaka, Oryzias latipes, is suitable for the study of hematopoiesis, because its embryos develop outside of the body, where blood cells can be easily examined under the microscope. In addition, its relatively short life cycle (2 -3 months), small size, and availability of several inbred lines make the medaka suited for genetic analysis (for reviews, see Ishikawa, 2000; Wittbrodt et al., 2002) .
In this study we identified and characterized a hypochromic anemia mutant, whiteout (who). The blood cells in the who mutant showed an elongated morphology with little hemoglobin activity. By genetic mapping and comparative synteny analysis, we found that who encodes d-aminolevulinic acid dehydratase. Thus, the who mutant represents a model for the human disease ADP.
Results
A hypochromic anemia mutant, whiteout (who), was identified during a screen for ethylnitrosoruea (ENU)-induced mutations affecting embryogenesis. Although the numbers of blood cells in such embryos was initially normal, it gradually decreased during embryonic and larval stages, resulting in lethality at approximately 1 week after hatching. Blood cells in the who mutant never developed a red color and had an elongated, and occasionally curved, morphology ( Fig. 1A -D) . In addition, the who mutant exhibited a yellow gallbladder that contained brownpigmented materials, rather than the yellowish-green gallbladder typical of the wild-type embryos (Fig. 1E,F) . Staining with o-dianisidine revealed that the who mutant had a little, if any, expression of hemoglobin (Fig. 1G,H) .
For genetic mapping, the who mutant in a Qurt background was crossed to the HNI strain fish, and F 1 fish were intercrossed or backcrossed to obtain F 2 embryos. The Qurt strain (Wada et al., 1998 ) is homozygous for the b allele, which causes unpigmented melanophores; whereas the HNI strain (Hyodo-Taguchi, 1980 ) is homozygous for B; which causes darkly pigmented melanophores. We found that the who phenotype cosegregated with the unpigmented melanophores, indicating that who was linked to b; which had been previously mapped to linkage group 12 (LG 12) (Naruse et al., 2000) . By further examining the linkage between who and LG12 markers, we mapped who to the vicinity of olgc1 (0.2 cM, n ¼ 966; Fig. 2A ).
Because the pufferfish, Fugu rubripes, is a close relative of medaka with an evolutionary distance of , 60 Myr (Nelson et al., 1994) , and the genome of this organism has been sequenced to over 95% coverage (Aparicio et al., 2002) , we searched for candidate genes of who in the pufferfish genome. The pufferfish olgc1 was included in the scaffold 865, which has been predicted to contain nine genes. Of these, the gene for d-aminolevulinic acid dehydratase (ALAD), which is located next to olgc1 ( Fig. 2A ) was considered to be a good candidate for who, since ALAD is the second enzyme in the heme synthetic pathway. By examining the medaka genomic DNA around the olgc1 gene, we found part of the alad gene next to olgc1. Using the sequence data of alad ORF in the EST database, we amplified alad cDNAs from the who mutant embryos and their wild-type siblings and directly sequenced the RT-PCR fragments. We found that who mutants carried a point mutation that substitutes Gln for Leu at position 251 ( Fig. 2B ). This mutation was confirmed by sequencing the genomic DNA in the who mutant embryos and their wildtype siblings (data not shown). We performed allele-specific PCR reactions, using the wild type-specific and the who mutant-specific PCR primers. As a result, we found that the alad gene was tightly linked to who (no recombinants among 966 meioses, Fig. 2C ). Furthermore, we injected an alad antisense morpholino (alad-MO) into the wild-type embryos at the 1-cell stage. Although the results were preliminary, most of the embryos injected with 1.0 ng alad-MO exhibited hypochromic anemia at 3 dpf, similar phenotype observed in the who mutant, whereas none of the embryos injected with a control morpholino exhibited such a phenotype. These analyses strongly suggest that the hypochromic anemia phenotype in the who mutant is caused by a loss of the alad gene function. To study the development of erythrocytes, we first examined the expression of the embryonic a-globin gene (em.a-0; Maruyama et al., 2002) during embryogenesis by whole mount in situ hybridization (Fig. 3A) . The em.a-0 gene first appeared in the ICM at the 9-somite stage (38 h post-fertilization [hpf] ). At the 12-somite stage (41 hpf), the em.a-0 expression separated into two stripes, one dorsal and the other ventral, in the regions of the developing dorsal aorta and the cardinal vein, respectively. After the onset of circulation, expression of the em.a-0 gene was found in the blood cells. In who mutants, expression of this gene was apparently normal at the mid-segmentation stages (Fig. 3B) , indicating that the severe reduction in the hemoglobin activity was not caused by reduced expression of em.a-0. The em.a-0 expression gradually decreased as embryogenesis proceeded, coinciding with the gradual decrease in the number of blood cells in the who mutant (data not shown).
We next examined expression of the alad gene, together with that of the gene for erythroid-specific isoform of deltaaminolevulinate synthase (ALAS2), the first enzyme in the heme synthetic pathway. The expression patterns of the alad and alas2 genes were similar to that pattern of em.a-0. These genes were expressed in the developing dorsal aorta and cardinal vein at the mid-segmentation stages, and were expressed in the blood cells at later stages in the wild-type embryos ( Fig. 3B; data not shown) . In who mutants, expression of the alad and alas2 genes was not affected at the 12-somite stage, but it gradually decreased thereafter, like that of the em.a-0 gene ( Fig. 3B ; data not shown). These expression patterns suggested that the alad gene is involved in the heme synthesis in the embryonic blood cells.
Discussion
Heme biosynthesis requires eight enzymatic steps to convert succinyl-CoA and glycine to the final product, heme. Mutations in the gene encoding the first enzyme in the heme synthetic pathway cause X-linked sideroblastic anemia in man, whereas porphyrias and related disorders are associated with deficiencies of the other seven enzymes. Mutational analyses of the blood cell development have been carried out in zebrafish, and the zebrafish hematopoietic mutants turned out to be useful models for human blood diseases (for reviews, see Amatruda and Zon, 1999; Dooley and Zon, 2000) . Mutations in the zebrafish alas2 gene, which encodes the first enzyme in the heme synthetic pathway, were shown to cause a microcytic hypochromic anemia in the sauternes mutant (Brownlie et al., 1998) . Other studies found that two photosensitive mutants, yquem and dracula, were defective in the fifth and eighth enzymes, respectively, in the heme synthetic pathway (Childs et al, 2000 ; Wang et al., 1998). The who mutation was mapped to LG12, 0.2 cM from olgc1 and 3.9 cM from OLb0801e. The pufferfish ortholog of olgc1 was found in Scaffold 865, which has been predicted to contain nine genes. Of these, the alad gene was thought to be a good candidate for who (see text). The alad gene was also found next to olgc1 in the medaka genome. (B) The RT-PCR fragments of the alad cDNA prepared from the wild type and the who mutant larvae were directly sequenced. The who mutant had a point mutation that substitutes Gln (CAG) for Leu (CTG) at position 251. The sequencing performed on the complementary strand is shown. (C) Allele-specific PCRs demonstrate that the mutation in the alad gene is tightly linked to who. The wild-type allele (upper panel) or the mutant allele (lower panel) of the alad gene was amplified from the wild type and the who mutant larvae. The wild type allele was never amplified from the who mutant larvae.
In this study we isolated and characterized the hypochromic anemia mutant, who. Blood cells in the who mutant had little hemoglobin activity, suggesting that synthesis of globin and/or heme may have been impaired. Genetic mapping and comparative synteny analyses revealed that who was tightly linked to the alad gene, which encodes the second enzyme in the heme synthetic pathway. The who mutant had a point mutation in the alad gene that substitutes Gln for Leu at position 251 (Fig. 2B) . These results strongly suggest that a loss of the alad function caused the hypochromic anemia phenotype in the who mutant.
It was previously shown that the Lys-252 in the active site of the human ALAD protein forms a Schiff's base linkage with the substrate (Gibbs and Jordan, 1986) . This Lys residue is equivalent to Lys-254 in the medaka ALAD protein. The who mutant carries Gln-251 rather than normal Leu-251 in the ALAD protein, and this residue is located 3 residues upstream of the active site Lys-254, suggesting that this substitution may affect interaction between the ALAD protein and its substrate. Further study is required to determine to what extent the enzyme activity is impaired by this mutation.
It is well known that human disease sickle cell anemia, which exhibits distorted sickle-shaped red blood cells, is caused by a mutation in the gene for b globin protein. When deoxygenated, the mutant hemoglobin proteins polymerize to form intracellular fibers, causing the sickle-cell deformity. The who mutant exhibited elongated, and occasionally curved, blood cell morphology. Although the molecular mechanism underlying the morphological abnormality is unknown, this abnormality may be caused by an accumulation of the globin proteins that are free of heme or perhaps by the accumulation of metabolic intermediates in the heme synthetic pathway. Recently, we identified seven additional hematopoietic mutants, two of which, lady finger (ldf) and ryogyoku (ryo), exhibited hypochromic anemia (Tanaka et al., 2004) . Complementation crosses indicated that ldf and ryo represent loci different from who. Interestingly, these mutants have an elongated and curved blood cell morphology, like the who mutant. It is noteworthy that none of the zebrafish mutants that exhibited hypochromic anemia displayed elongated blood cells (Ransom et al., 1996; Weinstein et al., 1996) , whereas all three hypochromic anemia mutants in the medaka show elongated blood cells. This observation may imply a difference in blood cell physiology between zebrafish and medaka.
In the medaka, a number of natural mutants have been collected for decades and several genes responsible for these mutants have been successfully identified (Fukamachi et al., 2001; Kondo et al., 2001; Loosli et al., 2001) . Recently, systematic ENU mutagenesis screens for mutations have been carried out by several research groups, and analyses of the isolated mutants are in progress. In this study, we found that information on the genomic sequence of the pufferfish facilitates identification of the genes responsible for mutants of medaka. Thus, the forward genetics approach in this teleost has become a practical way to study various biological processes. We are currently analyzing several of the above-mentioned hematopoietic mutants, which, as well as who, should be useful models to study the pathogenesis of human blood diseases.
Materials and methods

Fish maintenance and genetic screen for mutations
The Qurt strain, which was derived from the southern population (Wada et al., 1998) , was used for the genetic screen. Another strain, HNI (Hyodo-Taguchi, 1980) , which came from the northern population, was used for the mapping cross. Fish were maintained in systems with recirculating water at 26 8C. For collection of eggs, a pair of fish was kept in a 0.5 l breeding tank in the system. The obtained clutches were rubbed with paper towels to tear the attachment filaments off the chorion.
ENU mutagenesis and genetic screen for mutations affecting embryogenesis were performed as described (Ishikawa, 1996; Ishikawa et al., 1999) . who was identified by microscopic inspection as a Mendelian-inherited recessive lethal mutation that causes a hypochromic anemia phenotype.
Isolation and histological staining of blood cells and whole embryo staining with o-dianisidine
To collect blood cells, embryos and larvae were bled by tail amputation. For study of hemoglobin expression, whole embryos were stained with o-dianisidine, according to Detrich et al. (1995) .
Genetic mapping and analysis of the mutant allele
Using the high degree of polymorphisms between the strains Qurt and HNI, we performed genetic mapping. A who heterozygote on the Qurt background was crossed with a wild type HNI fish. F 1 fish were intercrossed or backcrossed to obtain F 2 embryos, from which genomic DNA was extracted as described for zebrafish (Talbot and Schier, 1999) . To examine genetic linkage between who and STS markers (http://mbase.bioweb.ne.jp/~dclust/ ml_base.html), the PCR fragments amplified from genomic DNA of the who mutants or wild-type siblings were digested with appropriate enzymes, if required, and separated on 3% agarose gels. The pufferfish genome sequences were obtained from http://www.ensembl.org/Fugu_rubripes/.
Genotyping of the who mutation was performed by allele specific PCR in two separate PCR reactions, using outer primers (sense primer: TGTCAGTGCTGAGCTACAGC and antisense primer: ACACGTTATACACAGCGAG) and either a wild type-specific (CCAGGCTTCACCATCA) or a mutant-specific (CCAGGCTTCACCATCT) antisense primer. PCR conditions were as follow: 94 8C (3 min); 10 cycles of 94 8C (30 s), 62 8C (45 s); 72 8C (1 min); 30 cycles of 94 8C (30 s), 55 8C (45 s), 72 8C (1 min); 72 8C (10 min).
Plasmid constructs and in situ hybridization
To synthesize digoxygenin-labeled RNA probes, we cloned RT-PCR fragments of em.a-0, alas1, and alad into a TA-cloning vector. Primers that amplify em.a-0 and alad were designed based on the EST sequences (Accession nos. AB026052 and BJ000194/BJ014680, respectively). Degenerate primers (GGTGCAGTAATGAYTAYCTGGG and GTAATTTATCGCYTGSACGTAGATG) were used to clone the alas2 gene. The nucleotide sequence of the cloned alas2 cDNA has been deposited in the DDBJ/EMBL/ GenBank under accession number AB154835. Wholemount in situ hybridization with digoxygenin-labeled RNA probes was done essentially as described previously (Inohaya et al., 1995) .
Morpholino oligonucleotide microinjections
An alad-MO (ACTGTGCTGGAGTCTGCATCTCTGA) and a control MO with 4-mispairs (ACAGTGGTG-GAGTCTGCTTCTGTGA) were obtained from Gene Tools LLC and were resuspended in water at 8.5 mg/ml. Stock solutions was diluted to working concentrations of 0.25 mg/ml in water containing 5 mg/ml phenol red. Approximately 4 nl of MO was injected into 1-cell stage embryonic cells using a pressurized microinjection device (PV820 Pneumatic Picopump, World Precision Instruments).
